InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,995.54
(
0.38%
)
US TECH 100
20,562.00
(
0.10%
)
Dow Jones
43,988.99
(
0.59%
)
Brent Oil
73.89
(
0.00%
)
Bitcoin
78,226.81
(
1.89%
)
Post# of 253566
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120698
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rwwine post# 662

Thursday, 12/18/2003 6:39:05 AM

Thursday, December 18, 2003 6:39:05 AM

Post# of 253566
It’s nice for EXEL that BMY has the confidence to renew the collaboration ahead of time, but these collaborations are not especially profitable for EXEL in the short run. I don’t see EXEL getting above $10 until there is more positive clinical data on the company’s in-house drug candidates. JMHO. Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up